Cellular metabolism
A small intravenous pilot measured changes in NAD-related metabolites. It did not establish more energy, better cognition or improved healthspan.
Read the publication
Physician-led care in the UAE
Related therapy · Pen
NAD+
NAD+ is a coenzyme, not a peptide. Human infusion work measures metabolism, while early injection data focus on short-term tolerability.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
Select the format
Get startedImportant safety informationSuitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this therapy
Where NAD+
has been studied.
The aging association reflects NAD biology. Metabolite measurements and short-term tolerability are not proof of more energy or improved healthspan.
Injection tolerability
A preliminary report includes a very small subcutaneous NAD+ group. It is not peer reviewed and cannot establish lasting clinical benefit or long-term safety.
Read the publicationSafety & suitability
Is NAD+ right for you?
Small pilot studies and preprints leave substantial uncertainty about long-term injection safety and clinical benefit.
Suitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
NAD+:
what has been studied.
Small studies have measured metabolism and short-term tolerability. They do not establish more everyday energy, better cognition or longer healthy life from NAD+ injections.
The study documented changes in circulating and urinary NAD-related metabolites.
11 men; eight received NAD+ · Intravenous
What remains uncertain
Read the studyIt did not demonstrate improved energy, cognition or anti-aging outcomes.
The NAD+ subgroup adds limited short-term injection-tolerability observations.
Includes a six-person subcutaneous NAD+ arm · Multiple substances and routes
What remains uncertain
Read the studyDo not attribute the larger or longer NR study to NAD+. This small, short subgroup does not establish clinical benefit.
About this evidence review
Evidence for oral NR or NMN, IV NAD+ and subcutaneous NAD+ is not interchangeable. The injected substance and route both matter.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss NAD+. Your clinician decides which preparation, checks and follow-up are relevant.
01
The preparation
What exactly are we considering?
What is the exact ingredient, formulation and strength, and how would it be used?
02
Your assessment
What needs checking first?
Which baseline checks, if any, would be appropriate for my health history?
03
Your follow-up
How will we review the plan?
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is NAD+ considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
Which NAD+ format is right for me?
Evidence for oral NR or NMN, IV NAD+ and subcutaneous NAD+ is not interchangeable. The injected substance and route both matter.
What should I know about the safety of NAD+?
Small pilot studies and preprints leave substantial uncertainty about long-term injection safety and clinical benefit.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
More in this area.
Explore other compounds discussed in these health topics, with the evidence for each.
DarDoc peptidesHealthy aging · Sleep & focus
Epitalon
Cell studies examine telomerase activity. An older clinical report explored a retinal condition, but human longevity benefits remain unestablished.
DarDoc peptidesRecovery · Healthy aging
Sermorelin
A small human study found changes in growth-hormone secretion and selected strength measures, with no change in body composition.
DarDoc peptidesMetabolism · Healthy aging
MOTS-C
A mitochondrial peptide studied in exercise biology. Animal treatment findings and measurements of naturally occurring MOTS-C in people are different kinds of evidence.
Bring your questions
Make your next step
a conversation.
Want to understand where NAD+ fits? Discuss the evidence, your health history and the options with DarDoc.
